FIELD: biotechnology.
SUBSTANCE: invention is a method for determining the degree of irritation of disinfectants on human skin, consisting in that Chang conjunctiva cell culture is dispersed in a 96-well panel of 100 mcl per well at a concentration of 1×105 cells/ml in nutrient Eagle-MEM with 10 % fetal calf serum (FCS). To form a monolayer of cells, the panel is incubated in a thermostat in an atmosphere of 5 % CO2 at 37 °C within 24 hours. After incubation, the culture medium is changed to medium containing 2 % FCS 100 mcl per well. Then the samples of disinfection agents (DA) are directly screened in the wells with Chang conjunctiva cells by the method of double serial dilutions in three repetitions per point, leaving the three control wells with a monolayer of cells free from the introduction of DA. Panel is placed in a thermostat, incubated in an atmosphere of 5 % CO2 at 37 °C within 24 hours. After incubation, the CM is removed from the wells, and 100 mcl of Eagle-MEM with 20 mcl of MTT reagent at a concentration of 5 mg/l is added to each well. After 4 hours of incubation in a thermostat in an atmosphere of 5 % CO2 at 37 °C MTT reagent medium is removed and 100 mcl of DMSO are added each time to dissolve the formazan reduced by the cells. After 5 minutes exposure, the optical density of the formazan solution in each well is measured on a spectrophotometer at a wavelength of 545 nm, then the optical density (OD) of the solutions obtained after cultivation, is compared with samples of DA with an optical density of solutions of control wells (ODc). In case of equality of OD and ODc by the value of the corresponding minimum non-toxic dilution, a judgment is made about the degree of irritant action of DA on human skin: absence, weak, moderate or pronounced.
EFFECT: provided opportunity to improve the accuracy of research.
1 cl
Title | Year | Author | Number |
---|---|---|---|
HUMAN CONJUNCTIVA CELLULAR CULTURE CHANG ATCC-CCL 20.2 FOR PREVENTION OF THE PHENOMENON OF TOXICITY OF EYE INSTILLATION IN CASE OF THE JOINT APPLICATION OF MEDICINAL DRUGS | 2017 |
|
RU2646100C1 |
METHOD FOR ENHANCING TUMOR CELL DEATH IN COMBINATION OF IONIZING RADIATION AND CDK INHIBITOR | 2020 |
|
RU2777869C2 |
METHOD FOR PRODUCING A CULTURE GROWTH SUPPLEMENT BASED ON HUMAN PLATELET LYSATE | 2017 |
|
RU2664478C2 |
METHOD FOR PRODUCING GROWTH ADDITIVE BASED ON THROMBOCYTE LYSATE FROM PLATELET OF DONORS TO MEDIUM FOR BUILD-UP OF CELLULAR WEIGHT OF STEM, PROGENITOR, DIFFERENTIATED AND TUMOR CELLS | 2016 |
|
RU2648162C2 |
METHOD FOR CELLULAR MATERIAL QUALITY ESTIMATION | 2016 |
|
RU2620969C1 |
INDOLE-3-CARBOXYLIC ACID DERIVATIVE HAVING ANTIVIRAL ACTIVITY ON SARS-CoV-2 | 2022 |
|
RU2820633C1 |
METHOD FOR EXTRACTING AND PURIFYING RECOMBINANT PROTEIN, AN ANALOGUE OF A HUMAN KAPPA-CASEIN FRAGMENT HAVING CYTOTOXIC ACTIVITY TOWARDS HUMAN CANCER CELLS | 2018 |
|
RU2693251C1 |
AGENT POSSESSING CYTOTOXIC ACTIVITY | 2019 |
|
RU2714932C1 |
4-(2,4-DIMETHOXYPHENYL)-2-(2-HYDROXYPHENYL)-5,6-DIHYDRO-4N-BENZO[H]CHROMENE-3-CARBOXYLIC ACID, HAVING CYTOTOXIC ACTIVITY | 2019 |
|
RU2707972C1 |
CYTOTOXIC AND ANTI-VIRAL ACTIVITY OF 3-ACYLOXIMETHYL-3-OXO-1-CYANO-2,3-SECO-2-NOR-TRITERPENOIDES | 2018 |
|
RU2682669C1 |
Authors
Dates
2019-03-13—Published
2018-05-29—Filed